4D Molecular Therapeutics

4D Molecular Therapeutics (4DMT) is a clinical-stage biotechnology company that develops targeted and evolved adeno-associated virus (AAV) vectors for gene therapy. It uses its Therapeutic Vector Evolution platform to create product candidates for ophthalmology, cardiology, and pulmonary diseases. Its lead programs include 4D-150 for wet age-related macular degeneration and diabetic macular edema.